PURPOSE: To examine risk perceptions (perceived risk of human papillomavirus [HPV], perceived risk of other sexually transmitted infections [STIs], and need for safer sexual behaviors) and to determine factors associated with these risk perceptions after HPV vaccination. METHODS: Data were collected at the baseline visit of an HPV-6, -11, -16, -18 vaccine clinical trial in 16-23-year-old HIV-infected young women (N = 99). Immediately after receiving the first vaccine dose, participants completed a confidential questionnaire that included three 5-item scales measuring perceived risk of HPV, perceived risk of other STIs, and need for safer sexual behaviors. Linear and logistic regression models were used to examine associations between baseline characteristics (demographic characteristics; cluster of differentiation antigen 4 (CD4(+)) count; HIV viral load; knowledge about HPV and HPV vaccines; sexual behaviors; and STI diagnosis) and each measure of risk perceptions. RESULTS: Most participants perceived themselves to be at lower risk for HPV (mean scale score = 19.5/50), most perceived that they were not at lower risk for other STIs (mean = 31.2/50), and the vast majority reported that there was still a need for safer sexual behaviors after vaccination (mean = 43.1/50). Multivariate analyses indicated that knowledge about HPV and HPV vaccines was associated with perceived need for safer sexual behaviors (OR = 1.05, 95% CI = 1.0-1.1). CONCLUSIONS: Although almost all young women in this study believed that safer sexual behaviors were still important after HPV vaccination, a subset believed they were at less risk for STIs other than HPV. Educational interventions are needed to prevent misperceptions and promote healthy behaviors after vaccination.
PURPOSE: To examine risk perceptions (perceived risk of human papillomavirus [HPV], perceived risk of other sexually transmitted infections [STIs], and need for safer sexual behaviors) and to determine factors associated with these risk perceptions after HPV vaccination. METHODS: Data were collected at the baseline visit of an HPV-6, -11, -16, -18 vaccine clinical trial in 16-23-year-old HIV-infected young women (N = 99). Immediately after receiving the first vaccine dose, participants completed a confidential questionnaire that included three 5-item scales measuring perceived risk of HPV, perceived risk of other STIs, and need for safer sexual behaviors. Linear and logistic regression models were used to examine associations between baseline characteristics (demographic characteristics; cluster of differentiation antigen 4 (CD4(+)) count; HIV viral load; knowledge about HPV and HPV vaccines; sexual behaviors; and STI diagnosis) and each measure of risk perceptions. RESULTS: Most participants perceived themselves to be at lower risk for HPV (mean scale score = 19.5/50), most perceived that they were not at lower risk for other STIs (mean = 31.2/50), and the vast majority reported that there was still a need for safer sexual behaviors after vaccination (mean = 43.1/50). Multivariate analyses indicated that knowledge about HPV and HPV vaccines was associated with perceived need for safer sexual behaviors (OR = 1.05, 95% CI = 1.0-1.1). CONCLUSIONS: Although almost all young women in this study believed that safer sexual behaviors were still important after HPV vaccination, a subset believed they were at less risk for STIs other than HPV. Educational interventions are needed to prevent misperceptions and promote healthy behaviors after vaccination.
Authors: Jessica A Kahn; Lili Ding; Bin Huang; Gregory D Zimet; Susan L Rosenthal; A Lindsay Frazier Journal: Pediatrics Date: 2009-06 Impact factor: 7.124
Authors: Thomas M Lampinen; Keith Chan; Robert S Remis; Maraki Fikre Merid; Melanie Rusch; Jean Vincelette; Ken Logue; Vladimir Popovic; Michel Alary; Martin T Schechter; Robert S Hogg Journal: CMAJ Date: 2005-02-15 Impact factor: 8.262
Authors: Jessica A Kahn; H Paul Cooper; Susan T Vadaparampil; Barbara C Pence; Armin D Weinberg; Salvatore J LoCoco; Susan L Rosenthal Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08 Impact factor: 4.254
Authors: Jessica A Kahn; Gregory D Zimet; David I Bernstein; Jeremy M Riedesel; Dongmei Lan; Bin Huang; Susan L Rosenthal Journal: J Adolesc Health Date: 2005-12 Impact factor: 5.012
Authors: David E Ostrow; Kelly J Fox; Joan S Chmiel; Anthony Silvestre; Barbara R Visscher; Peter A Vanable; Lisa P Jacobson; Steffanie A Strathdee Journal: AIDS Date: 2002-03-29 Impact factor: 4.177
Authors: Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Gina S Ogilvie; Felicia Phan; Heather N Pedersen; Simon R Dobson; Monika Naus; Elizabeth M Saewyc Journal: CMAJ Date: 2018-10-15 Impact factor: 8.262
Authors: Shalanda A Bynum; Stephanie A S Staras; Teri L Malo; Anna R Giuliano; Elizabeth Shenkman; Susan T Vadaparampil Journal: J Adolesc Health Date: 2013-09-21 Impact factor: 5.012
Authors: Jessica A Kahn; Jiahong Xu; Bill G Kapogiannis; Bret Rudy; René Gonin; Nancy Liu; Craig M Wilson; Carol Worrell; Kathleen E Squires Journal: Clin Infect Dis Date: 2013-05-10 Impact factor: 9.079